Диагностический алгоритм использования серологического опухолевого маркера SCC у больных раком шейки матки
![Диссертация: Диагностический алгоритм использования серологического опухолевого маркера SCC у больных раком шейки матки](https://westud.ru/work/2529102/cover.png)
Диссертация
Значимость SCC и TPS в мониторинге больных РШМ с целью доклинического выявления рецидива изучена еще меньше. Лишь в последние годы активно исследуют роль SCC в динамике. Однако количество публикаций, посвященных этому вопросу, пока невелико. Рецидив РШМ по данным ряда авторов сопровождается повышением SCC в 66−90% случаев, при этом некоторые исследователи отмечают рост маркера до клинического… Читать ещё >
Содержание
- СПИСОК СОКРАЩЕНИЙ
- ГЛАВА I. Обзор литературы
- СЕРОЛОГИЧЕСКИЕ ОПУХОЛЕВЫЕ МАРКЕРЫ РАКА ШЕЙКИ МАТКИ
- 1. 1. Серологический опухолеассоциированный маркер SCC
- I. 1.1. Общая характеристика SCC, экспрессия в норме и при различных патологических состояниях
- 1. 1. 2. SCC в уточняющей диагностике и мониторинге больных плоскоклеточным раком шейки матки
- 1. 2. Другие опухолеассоциированные маркеры при раке шейки матки и их использование в комбинации с SCC
Список литературы
- БелецкаяА.В., Бернбейн Б. А., Райхлин Н. Т. и др. Базальноклеточ ный перекрестнореагирующий антиген в нормальных и опухолевых тканях человека. // Архив патологии.-1982.-том 1.-С.330−334.
- Бохман Я.В. Руководство по онкогинекологии.// Санкт-Петербург.-«Фолиант». — 2002.-542 с.
- Винокуров В.Л., Жаринов Г. М., Валькович А. А. и др. Профилактика лучевых повреждений прямой кишки и мочевого пузыря у больных раком шейки матки.// Вопросы онкологии.-2000.-том36.-№ 9.-с.1119−1120.
- Вишневская Е.Е., Косенко И. А. Отдаленные результаты комплексной терапии больных раком шейки матки с неблагоприятным прогнозом.// Вопросы онкологии.-1999.-том 45.-№ 4.-с.420−423.
- Вишневская Е.Е. Предопухолевые заболевания и злокачественные опухоли женских половых органов.// Минск.- «Высшая школа». -2002.- 416 с.
- Габелов А.А., Жаринов Г. М. Зависимость результатов лучевого лечения больных раком шейки матки от объема опухоли.// Медицинская радиология.-1998.-№ 3 .-с.33−35.
- Гельштейн В.И. Иммуноморфологический анализ опухолей челове ка с помощью моноклональных антител.// Вестник РОНЦ им. Н.Н.Б лохина.-2003 .-№ 3 .-с.З 7−41.
- Девятченко Т.Ф., Филатова Н. С., Коротина Л. А. и др. Особенности локализации и диагностики рецидивов рака шейки матки.// Частные вопросы практической онкологии.- Волгоград.-1999.-том 51.-выпуск 3.-С.50−53.
- Козаченко В.П. Рак шейки матки.// Современная онкология.-2000.-том 2.-№ 2.-с. 43−48.
- Костромина К.Н. Современное состояние и перспективы развития лучевой терапии гинекологического рака.// Медицинская радиоло-гия.-2001.-том 46.-№ 1.-с.48−51.
- Мкртычян JI.C. Сочетанная лучевая и комплексная терапия местно-распространенного рака шейки матки: Автореферат дисс. канд. мед. наук.-0бнинск.-2001.-39с.
- Новик В.И., Сафронникова Н. Р., Урманчеева А. Ф. и др. Пути повышения эффективности цитологического скрининга рака шейки матки. // Материалы всероссийского симпозиума."Новые информационные технологии в онкологической статистике". -Спб.-2001.-е. 195−197.
- Новик В.И. Эпидемиология рака шейки матки, факторы риска, скрининг.//Практическая онкология.-2002.-том 3.-№ 3.-с.156−65.
- Новикова Е.Г. Диагностика предраковых заболеваний и начальных форм рака шейки матки, влагалища и вульвы (клинические лекции).// М.-МедПресс.-1999.-153−159.
- Новикова Е. Г. Антипов В.А. Рак шейки матки. // Избранные лекции по клинической онкологии. Под редакцией акад. РАМН В. И. Чиссова и проф. С. Л. Дарьяловой.-М.-2000.-с.501−521.
- Новикова Е. Г, Чиссов В. И., Антипов В. А. и др. Органосохраняющее лечение в онкогинекологии.// Москва.- «Видар-М». -2000.- 112 с.
- Петрова Г. В. Показатели онкологической помощи больным раком шейки матки в России.// Российский онкологический журнал.-2003.-№ 5.-с.36−38.
- Пытель Ю.А., Борисов В. В., Симонов В. А. Физиология человека. Мочевые пути. // Москва.- «Высшая школа». -1992.-288с.
- Урманчеева А.Ф., Мерабишвили В. М., Сельков С. А. и др. Эпидемиология и диагностика рака шейки матки.// Акушерство и гинекология.-2001.-том 25.-выпуск 1.-С.80−86.
- Храйчик Дональд Е., Седор Джон Е., Ганц Майкл Б. Секреты нефрологии.// Москва.- «Невский диалект». -2001.-303с.
- Чиссов В.И., Старинский В.В, Петрова Г. В. Состояние онкологической помощи населению России в 2003 году.// М.-2004.-196 с.
- Чиссов В.И., Старинский В.В, Петрова Г. В. Злокачественные новообразования в России в 2003 году (заболеваемость и смертность).// М.-2005.-256 с.
- Шейнман Джеймс А. Патофизиология почки.// Москва.- «Невский диалект». — 1999.-206с.
- Agarwal S., Sharma S. Localisation of CEA in utherine cervical neoplasia.// Indian J Med Res.-1990.-Vol.92.-p.452−5.
- Alberts В., Bray D., Lewis J. et al. Molecular biology of the cell// Garland Publishing, Inc.-1994.-1294p.
- Alessandro R., Roselli M., Ferroni P. et al. Serum TPS: a complementary tumor marker to CA 125 in the management of breast cancer// Breast Cancer Res Treat.-2001.-vol.68.-N l.-p.9−19.
- Bando M., Tani K., Kohrai F. et al. A case of sarcoidosis with elevated SCC antigen in the serum and broncho-alveolar lavage fluid witch was difficult to distinguish from lung cancer. // Nichon-Kuoby-Shikkan-Gakkai
- Zasshi.-1994.-vol.32.-N l.-p.95−100.
- Bae S., Namkoong S., Jung J. et al. Prognostic significance of pretreat-ment SCC antigen and CEA in squamous cell carcinoma of the uterine cervix. // Gynaecol-Oncol.-1997.-vol.64.-N 3.-p.418−424.
- Borras G., Molina R., Xercavins J. et al. SCC antigen in cervical cancer. // Eur-J-Gynaecol-Oncol.-1999.-vol.l3.-N5.-p.414−418.
- Borras G., Molina R., Xercavins J. et al. Tumor antigens CA 19−9,CA 125 and CEA in carcinoma of the uterine cervix.//Gynecol 0ncol.-2000.-Vol.57.-N 2.-p.205-l 1.
- Bouzid К., Mahfouf H. Proc.ASCO.-2000.-vol.l9.-p.391.-abstract 1549.
- Burnett A., Roman L., Garcia A. et al. Gecitabine and cisplatin in patients with advanced squamous cell carcinoma of the cervix.-Gynecology On-cology.-2000.-vol.76.-N 1 .-p.63−66.
- Callet N., Cohen-Solal Le Nir C., Berthelot E. et al. Cancer of the uterine cervix: sensitivity and specificity of serum CYFRA 21−1 determinations.// Eur J gynaecol oncol.-1998.-Vol.19.-N 1.- p.50−6.
- Cataltepe S., Luke C., Silverman G. et. al. TD-10 SCC antigen workshop. // Tumor Biol.-2002.-vol.23.-p. 17.
- Ceriani L., Giovanella M., Salvadore M. et al. TPS immynoassay in the diagnosis and clinical staging of prostatic carcinoma // Int J Biol Markers.-1997.-vol.12.-N L-p.27−34.
- Chang C., Wu H., Yen R. et al. TPS as a tumor marker renal cell carcinoma // Anticancer Res.-2002.-vol.25.-N 5.-p.2949−50.
- Chen M., Lin J., Yu W. et al. Relation between the serum TPS level and the biological demeanour of lung cancer. // Zhonghua Jie He He Hu.-2002.-vol.25.-N5.-p.262−4.
- Correlate M., Arnberg H., Blockx P. et al. Clinical profile of a new monoclonal antibody-based immunoassay for TPA // Int J Biol Markers.-1994.-vol.9.-N 4.- p.231−8.
- Crawford E., Deiantoni E., Etzioni R. et al. Serum PSA and digital rectal examination for early detection of prostata cancer in a national community-based program // Urology.-1996.-vol.47.-p.863−869.
- Crawford R., lies R., Carter P. et al. The prognostic significance of beta human chorionic gonadotropin and its metabolites in women with cervical carcinoma.// J Clin Pathol.- 1998.-Vol.51.-N9.-p.685−8.
- Crombach G., Scharl A., Vierbuchen M. et al. Detection of SCC antigen in normal squamous epithelia and in squamous cell carcinomas of the uterine cervix. // Cancer.-1989.- vol.63.-N 7.- p.1337−1342.
- Duk J., de-Bruijn H., Croinier K. et al. Cancer of the uterine cervix: sensitivity and specificity of serum SCC antigen determinations. // Gynecol-Oncol.-1996.-vol.39.-N 2.-p. 186−194.
- Ebert W., Hoppe M., Muley T. et al. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21−1, TPA-TP, CEA and NSE.//Anticancer Res.-1997.-vol.17.-N 4.-p.2875−8.
- Eirnarson R., Lindman H., Bergh J. et al. Use of TPS and CA 15−3 assays for monitoring chemotherapy in metastatic breast cancer patients. // Anticancer Res.-2000.-vol.20.-N 6.-p.5089−93.
- Esajas M., Duk J., de-Bruijn H. et al. Clinical value of routine serum SCC antigen in follow-up of patients with early-stage cervical cancer. // J-Clin-0ncol.-2001 .-vol. 19.-N 19.- p.3960−3966.
- Eskelinen M., Kataja V., Hamalainen E. et al. Serum tumor markers CEA, AFP, CA 15−3, TPS in diagnosis of breast cancer.// Anticancer Res.-1997.-vol.17.-N 2.-p.l231−4.
- Fateh-Moghadam A., Stieber P. Sensible use of tumor markers.-J.Hartman (ed).-Basel.-Switzeland: Springer Verlag.-Elitiones Roche.-1993.-78p.
- Fontana X., Lagrange J., Francois E. et al. Assesment of SCC antigen as a marker of epidermoid carcinoma of the anal canal. // Dis-Colon-Recrum.-1991 .-vol.34.-N 2.-p. 126−131.
- Fukasawa I., Kousaka N., Kun Z. et al. Tumor markers in uterine cancers.// Gan To Kagaku Ryoho.-2002.-Vol.29.-N2.-p.333−40.
- Gaarenstroom K., Bonfrer J., Korse C. et al. Value of CYFRA 21−1,TP A and SCC antigen in predicting extracervical disease and prognosis in cervical cancer.// Anticancer Res.-1997.-vol.17.- N 4.-p.2955−2958.
- Gaarenstroom K., Kenter G., Bonfrer J. et al. Can initial serum CYFRA 21−1, SCC antigen and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?// Gynaecol-0ncol.-2000.-vol.77.-N 1.- p.164−170.
- Giai M., Roagna R., Ponzone R. et al. TPS and CA 15−3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res.-1999.-vol.16.-N 2.-P.875−81.
- Giovagnoli M., Valli C., Vecchione A. Immunogistochemical expression of TPS antigen in normal and neoplastic tissues.// Anticancer Res.- 1994.-vol. 14.-p.635−641.
- Gitsch G., Kainz C., Joura E. SCC antigen, TATI and TPS in follow up of stage III cervical cancer.// Anticancer Res.-1998.-vol.12.-p. 1247−9.
- Gonzale-Quintela A., Mella C., Perez L. Increased serum TPS in al-cogolics: a possible marker of alcogolic hepatitis.//Alcohol Clin Exp Res.-2000.-vol.24.-N 8.-p. 1222−6.
- Gorze P., Vahrson H. Nishida T. Sugnificance of determination of SCC antigen in the follow-up of patients with cancer of the uterine cervix. // Orv-Hetil.-1992.-vol. 133.-N 50.-p. 3191−3194.
- Griesenberg P., Nurnberg R., Bahlo M. et al. CEA, TPS, CA 19−9 and CA 72−4 in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.// Anticancer Res.-2002.-vol.19.-n 4.-p.2443−50.
- Gris J., Xercavins J., Trillo. et al. Study of the SCC antigen in benign diseases. // Med-Clin.-1996.- vol.106.-N 6.-p.205−208.
- Hameed A., Miller D., Muller C. et al. Frequent expression of beta-human chorionic gonadotropin in squamous cell carcinoma of the cervix.// Int J Gynecol Pathol.-2000.-vol. 18.-N4.-p.381 -6.
- Hefler L., Obermair A., Tempfler C. et al. Serum concentrations of SCC antigen in patients with vulvar intraepithelial neoplasia and vulvar cancer.// Int-J-Cancer.-1999.-vol.84.-N 3.-p.299−303.
- Hefler L., Tempfer C., Hauster G. et al. Cytokeratin tumor markers in ovarian carcinoma: TPS and M3/M21// Wien Klin Wochenschr.-2000.-vol. 110.-N 18.-p.635−40.
- Henry R., Dodd J., Tyler J. et al. SCC tumor marker and its relationship to clinical stage in squamous cervical cancer. // Aust-N-Z-Obstet-Gynaecol.-1997.-vol.27.-N 4.-p.33 8−340.
- Hirata S., Yamazaki K., Yokoyama Y. et al. Studies on SCC antigen in patients with esophageal carcinoma. // Nippon-Geka-Gakkai-Zasshi.-1999.-vol.90.-N 2.-p.267−272.
- Hobarth K., Hakas A., Kramer G. et al. TPS in renal cell carcinoma // Eur Urol.-1998.-vol.30.-N l.-p.89−95.
- Ho Y., Hsieh J., Tasi C. TPS and SCC for early prediction recurrence in lung squamous cell carcinoma. // Lung.-2000.-vol.178.-N 2.-p.75−80.
- Horman R., de Medeiros S., Amato F. et al. Beta-core fragment of human chorionic gonadotropin in cervical intraepithelial neoplasia.// Gynecol Oncol.- 1990.-Vol.49.-Nl .-p. 16−8.
- Hsieh C., .Chang D., Huang S. et al. SCC antigen in gynecologic malignancies with special reference to cervical cancer. // Taiwan-Yi-Xue-Hui-Za-Zhi.-1989.-vol.88.-N8.-p.797−800.
- Hung Y., Shiau Y., Chang W. et al. //Early predicting recurrent cervical cancer with combination of tissue polypeptide specific antigen (TPS) and squamous cell carcinoma antigen (SCC) // Neoplasma.2002.-vol.49.-N 6.-p.415−417.
- Ikeda K. Clinical and fundamental study of a SCC antigen for esophageal squamous cell carcinoma. //Nippon-Geka-Gakkai-Zasshi.-1991.-vol.92.-N 4.-p.387−396.
- Inaba N., Fukasawa j., Okajima Y. Immunoradiometrical measurement of TPS in normal, healthy, nonpregnant and pregnant Japanese women. // Asia Oceania Obstet Gynaecol.-2001.-vol.19.-N 4.-p.459−66.
- Kassanos D., Botsis D., Rizos D. et al. TPS throughout normal pregnancy. // Anticancer Res.-2000.-vol.20.-N 3.-p.2129−31.
- Kassim S., Fawzy H., El Rassad M. et al. Telomerase activity, and TPS in Egyptian breast cancer patients. // Clin Biochem.-2001.-vol.34.-N 6.-p.499−504.
- Kato H. Expression and function of SCC antigen. // Anticancer Res.-1996.-vol.16.-N 48.-p.2149−2153.
- Kato H. SCCA1 and SCCA2 are proteinase inhibitors that map to the ser-pin cluster at 18q21.3// Tumor Biol.-1998.-p. 478−479.
- Kelomiemi E., Rintala E., Finne P. et al. TATI as a prognostic factor during follow-up of bladder cancer.// Urology.-2003 .-vol.62.-N 2.-p. 219−53.
- Khoo S., Daunter В., Mackay E. CEA and beta 2-microglobulin as serum tumor markers in women with genital cancer.// Int J Gynaecol Obstet.-1979.-Vol. 16.-N5 .-p.3 88−93.
- Kikkawa F., Nawa A., Tamakoshi K. et al. Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary. // Cancer.-1998.-vol.82.-N ll.-p.2249−2255.
- Kinugasa M., Nishimura R., Koizumi T. et al. Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers. // Jpn J Cancer Res.-1995.- vol.86.-N8.-p.783−9.
- Koch Т., Eiffert H., Spindler M. Relevance of the new tumor marker SCC for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck. // HNO.-1999.-vol.37.-N 1 l.-p.454−459.
- Kramer G., Steiner G., Madersbacher S. et al. Serial TPS antigen determinations in the follow-up of hormone treated carcinoma of the prostata. // J Urol.-1997.-vol. 158.-N 4.-p. 1446−51.
- Kulpa J., Wojcik E., Reinfuss M. et al. CEA, SCC CYFRA 21−1 and NSE in squamous cell lung cancer patients.// Clin Chem.-2002.-Vol.48.-N 11.-p.1931−7.
- Lara P., Cuyas J. The role of SCC antigen in the management of laryngeal and hypopharyngeal cancer. // Cancer.-1995.-vol.76, — N 5.-p.758−764.
- Leccuru F., Neji K., Robin F. et al. Microinvasive carcinoma of the cervix. Racionale for conservative treatment in early squamous cell carcinoma. // Europ.J.Gynecol. Oncol.-2000.-vol.18.-N 6.-p.465−470.
- Lehtevirta P., Turpeinen U., Stenman U. Effect of intracavitary radiotherapy on tumor-associated trypsin inhibitior (TATI) in patients with cervical and endometrial cancer.// Gynecol Oncol.-1990.-Vol. 38.-N1.- p.110−3.
- Lehtevirta P., Viinikaa L., Vlikorkala O. Comparison between SCC and CA 125 in patients with carcinoma of the cervix.// Gynecol 0ncol.-2000.-Vol.37.-N2.-p.276−8.
- Leminen A. Tumor markers CA 125, CEA and TATI in patients with cervical cancer.// Gynecol Oncol.-1990.-Vol.39.-N3.-p.358−63.
- Mady E. Cytokeratins as serum markers in Egyptian bladder cancer. A comparison of Cyfra 21−1, TPA and TPS. // Int J Biol Markers.-2001.-vol.16.-N 2.-p.l30−5.
- Mainman M., Feuer G., Fruchter R., et al. Value of SCC antigen levels in invasive cervical carcinoma. // Gynecol-Oncol.-1989.-vol.34.-N 3.-p.312−316.
- Makrantonakis P., Pectasides D., Aggrouridakis C. et al. SCC in squamous cell cancer of head and neck // Am-J-Clin-Oncol.-1999.-vol.22.-N 6.-p.542−549.
- Malamitsi-Puchner A., Vazeou-Gerasimidi A., Sarandakou A. TPS antigen serum concentrations in Children, Adolescents and young Adults with Type I Diabetes.// Diabetes Care.-2002.-Vol.25.-p.240−41.
- Mao Y., Zhang D., Zhao X. Significance of CEA, SCC and CYFRA 21−1 serum test in esophageal cancer. // Zhonghua Zhong Liu Za Zhi.- 2003.-vol.25.-N 5.-P.457−460.
- Marks L., Carroll P., Dugan T. et al. The response of the urinary bladder, urethra and ureter to radiation and chemotherapy.// Int.J.Radiation Oncol. Biol.Phys.-1999.-vol.31 .-N 5.-p. 1257−1280/
- Marrink J., Oosterom R., Bonfrer H. et al. TPS: a discriminative parameter between prostata cancer and benign prostatic hypertrophy. // Eur J Cancer.- 1998.-vol.29.-N 4.-p.570-l.
- MashokaT., Matueda Y., Ookawa H. et al. The measurement of SCC antigen in squamous cell carcinoma of the lung. // Gan-No-Rinsho.-1995.-vol.31.-N 8.-p.914−918.
- Massuger L., Koper N., Thomas C. et al. Improvement of clinical staging in cervical cancer with SCC and CA 125 determinations. // Gynecol On-col.-1997.-Vol.64.-N3.-p.473−6.
- Medl M., Ogris E., Peters-Engl C. et al. TATI as a marker of ovarian cancer. // Br J Cancer.-2000.- vol. 71.-N 5.-p. 1051−4.
- Meria P., Toubert M., Cussenot O. et al. TATI and renal cell carcinomaII Eur Urol.-1999.-vol.27.-N 3.-p. 223−6.
- Meydanli M., Kucukali Т., Usubutum A. et al. Epithelioid trophoblastic tumor of the endocervix: a case report.// Gynecol 0ncol.-2002.-vol.87.-N2.-p.219−24.
- Meyer W., Eiermann P., Stieber P. et al. Experinces with the SCC antigen? A new tumor marker of cancer of the uterine cervix.// Geburtshilfe-Frauenheilku.-1989.-Vol.49.-N7.-p.625−9.
- Micke O., Prott F., Schafer U. et al. The impact of SCC antigen in the follow-up after radiotherapy in patients with cervical cancer. // Anticancer-Res.-2000.-vol.20.-N 6.-p.5113−5115.
- Mishael M., Klein В., Sadikov E. et al. Initial TPS serum level as indicator of relapse and survival in colorectal cancer. // Anticancer Res.-1998.-vol.18.-N 3.-p.2101−5.
- Molina R., Fiella X., Lejarcegui J. et al. Prospective evaluation of SCC and CEA as prognostic factors in patients with cervical cancer.// Tumor Biol.-2003.-Vol.24.-N3.-p. 156−64.
- Moreno S., Chicharro A., Torronteras S. et al. Advanced regarding tumor markers in bladder cancer. // Actas Urol Esp.-1997.-vol.21.-N 3.-p.l95−205.
- Nather A., Sami A., Hefler L. et al. Serum levels of SCC as a predictor of inguinofemoral lymph node metastasis in patients with vulval cancer.// J Reprod Med.-2002.-Vol.47.-N 9.-p.718−20.
- Ngan H., Cheung A., Lauder J. et al. Prognostic significance of serum tumor markers in carcinoma of the cervix. // Tumor Biol.-1998.-vol.19.-p.439−444.
- Nilsson O., Roijer K., Nilsson K. Establishment of monoclonal antibodies and immunoassays for different forms of SCC antigens. // Tumor Biol.-1998.-vol.l.-p.218.
- Nilsson O., Roijer E., Nilsson K. Characterisation of ISOBM TD-10 SCCA monoclonal antibodies. // Tumor Biol.-2002.-vol.23.-p.15.
- Niklinski J., Furman M., Landanski J. et al. Prognostic value of pretreat-ment CEA, SCC antigen and CA 19−9 levels in sera of patients with non-small cell lung cancer. // Eur-J-Cancer-Prev.-2000.-vol.l.-N 6.-p.401−406
- Numa F., Takeda O., Nakata M. et al. Tumor necrosis factor-alpha stimulates the production of SCC antigen in normal squamous cells. // Tumor Biol.-1996.-vol. 17.-N 2.-p.97-l 01.
- Numahara Т., Nakashima K., Yamamoto S. et al. Significance of SCC antigen in psoriasis and generalized eczema. // Dermalogica.-1989.-vol.178.-N 2.-p.73−74.
- Ohno Т., Nakayama Y., Nakamoto S. et al. Measurement of serum SCClevels as a predictor of radiation response in patients with carcinoma of theuterine cervix.// Cancer.-2003.-vol.97.-N 12.-p.3114−3120.
- Padungsutt P., Thirapagawong C., Senapad S. et al. Accuracy of TPS in the diagnosis of ovatian malignancy. // Anticancer Res.-2000.-vol.20.-N 2.-P.1291−5.
- Pras E., Willemse D., Carninus A. et al. SCC antigen and CYFRA 21−1 in cervical cancer treatment. // Int-J-Radiat-Onc-Biol-Phys.-2002.-vol.52.-N L-p.23−32.
- Pasanen P., Eskelinen M., Partanen K. et al. Diagnostic value of TPS in patients with pancreatic carcinoma. // Tumor Biol.-1999.-vol.15.-N 1.-p.52−60.
- Pattaranutaporn P., Chansilpa Y., Tangkarat S. et al. Serum TPS in patients with cervical carcinoma: preliminary report.// Anticancer Res.-1997.-vol. 17.-p.2309−12.
- Pattaranutaporn P., Chansilpa Y., Sukkasem M. et al. Serum TPS in loco-regional failure and distant metastasis of cervical carcinoma.// j Med Assoc Thai.-2000.-vol.83.-p.1011−5.
- Pectasides D., Economides N., Bourazanis J. et al. SCC antigen, TATI and CEA for monitoring caervical cancer.-Am J Clin Oncol.-1994.-vol.17.-N 4.-p.307−312.
- Pesanen P., Eskelinen M., Kuljn A. et al. TATI in patients with colorectal cancer: a comparison with CEA, С A 50 and С A 242.// Scand J Clin Lab Invest.-1999.-vol.55.-N 2.-p.119−24.
- Peters-Engl ., Medl M., Ogris F. et al. TATI and CA 125 in patients with epithelial ovarian cancer. // Anticancer Res.- 2000.- vol. 15.- N 6.- p. 2727−30.
- Pina Т., Zapata Т., Lopez I. et al. Tumor markers in lung cancer. // Clin Biochem.-1999.-vol.32.-N 12.-p. 1465−74.
- Pras E., Willemse P., Canrinus A. et al. Serum SCC antigen and CYFRA 21−1 in cervical cancer treatment. // Int J Radiat Oncol Biol Phys.-2002.-Vol.52.-Nl .-p.23−32.
- QuillinenV., Raoul J., Laurent J. et al. Comparison of CYFRA 21−1, TPA and SCC in esophageal squamous cell carcinoma.// Oncol Rep.-1998.-vol.5.-N 6.-p.1561−1565.
- Rebhandl W., Felberbaner F., Paya K. TPS in pediatric patients: assessment of normal values. // Med Pediatr Oncol.-1997.-vol.29.-N 3.-p.218−221.
- Rebhandl W., Paya K., Felberbauer F. et al. TPS in pediatric malignancies. // Anticancer Res.-1997.-vol.17.-N 4.-p.2865−8.
- ReinmuthN., Brandt В., Semik M. et al. Prognostic impact of CYFRA 211 and other serum markers in completly resected non-small lung cancer.// Lung cancer.-2002.-Vol.36.-N3.-p.265−70.
- Roijer E., Kosinska U., Andersson J. et al. Rearrangement of SCC antigen genes // Tumor Biol.-1998.-vol.-p. 84.
- Roijer E., Kosinska U., Andersson J. et al. Rearrangement of SCC antigengenes- detection of SCCA fusion transcripts. // Tumor Biol.- 2003.лvol.24.-p.46−52.
- Rosati G., Riccardi F., Tucci A. Use of tumor markers in the management of head and neck cancer. // Int-J-Biol-markers.-2000.- vol.15.-N 2.-p. 179 183.
- Rose P., Baker S., Fournier L. et al. Serum SCC antigen levels in invasive cervical cancer: prediction of response and recurrence. // Am-J-Obstet-Gynecol.-2001 .-vol. 168.-N 3 .-p.942−946.
- Rose P., Bundy В., Watkins E. et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally-advanced cervical cancer.// N. Engl J.Med.-1999.-vol.340.-p. 1144−1153.
- Rydlander L., Ziegler E., Bergman T. et al. Molecular characterization of a TPS epitope and its relationship to human cytokeratin 18. // Eur J Bio-chem.-1996.-vol.24.-Nl.-p.3 09−14.
- Salman Т., el-Ahmady O., Sawsan M. et al. The clinical value of serum TPS in gynecological malignances.// Int J Biol Markers.-1997.- vol. 10.-p.81−6.
- Sanchez-de-Cos-Escuin J., Lopez-Parra S., Desdier-Vicente C. et al. Diagnostic utility of CEA, NSE and SCC antigen in malignant pleural effusion. // An-Med-Interna.-1996.-vol. 13.-N 8.-p.369−373.
- Sanchez-de-Cos J., Masa F., de-la-Cruz J. et al. SCC antigen in the diagnosis and prognosis of lung cancer. // Chest.-1999.-vol.l 05.-N 3.-p.773−776.
- Sanders D., Ferryman S., Bryant F. et al. Patterns of CEA-related antigen expression in invasive squamous carcinoma of the cervix.//J Pathol.-1993.-Vol.171.-Nl.-p.21−6.
- Sarandakou A., Kontoravdis A., Kontodeorgi Z. et al. Expression of CEA, CA125 and SCC antigen by biological fluids associated with pregnancy. // Eur- J-Obstet-Gynecol-Reprod-biol.-1992.-vol.44.-N3.-p.215−220.
- Sarandakou A., Phocas J., Botsis D. et al. Tumor-associated antigens CEA, CA 125, SCC and TPS in gynecological cancer. // Eur J Gynaecol Oncol.-1998.-vol.l9.-p.73−77.
- Schmidt-Rhode P., Shulz K., Sturm G. et al. SCC antigen for monitoring cervical cancer.// Int-J-Biol-Markers.-2003.-vol.3.-N 2.-p.87−94.
- Sedlaczek P., Fiydecka J., Gabiys M. et al. Comparative analysis of CA 125, TPS in serum, cyst and ascitic fluids from patients with ovarian carcinoma. //Cancer.-2002.-vol.95.-N 9.-p. 1886−93.
- Sheard M., VojtesekB., Simickova M. et al. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21−1) into the extracellular space during apoptosis.// J Cell Biochem.-2002.-vol.85.-p.670−677.
- Slesak В., Harlozinska-Szmyrka A., Knast W. et al. TPS, a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19−9.// Cancer.-2000.-vol.89.-N l.-p.83−88.
- Slietz G., Tempter C., Kainz C. et al. TPS and CA 125 in the follow-up of ovarian cancer. // Anticancer Res.-1998.-vol.15.-N 3.-pl 127−9.
- Solakidi S., Timakos D., Petraki K. et al. Co-expression of trypsin and TATI in colorectal adenocarcinomas.//Histol Hystopatol.-2003.-vol.18.-N 4.-p. 1181−8.
- Solakidi S., Dessypris A., Stathopoulos G. et al. TATI, CEA and eel trypsin in patients with gastrointestinal malygnances.// Clin Biochem.-2004.-vol.37.-N 1.-p.56−60.
- Stamey Т., Pitfalls in interpreting PSA velocity // Cancer.-1996.-v.74.-p.337−347.
- Strauss H., Laban C., Lautenschlager C. SCC antigen in serum as a independent prognostic factor in operable squamous cell carcinoma of the cervix.//Eur J Cancer.- 2002.-vol.38.-N 15.-p. 1987−91.
- Stenman J., Hedstrom J., Grenman R. Relative levels of SCCA2 and SCCA1 mRNA in primary tumors predicts reccurents disease in squamous cell cancer of the head and neck.// Int J Cancer.- 2001.-vol.95.-N l.-p.39−43.
- Sturgeon C., Seth J., Paterson G. et al. Serological markers for metastatic breast cancer. //Dis Markers.-1998.-vol.ll.-N 5.-p.217−23.
- Suminami Y., Nawata S., Kato H. Biological role of SCC antigen.// Tumor-Biol.-1998.-vol. 19.-p.488−493.
- Suzuki K., Suzuki Т., Akiyama J. et al. Serum and pleural SCC antigen levels in patients with pulmonary tuberculosis. // Kekkaku.-1993.-vol.68.-N9.-p.551−557.
- Suzuki Y., Nakano Т., Ohno T. et al. Serum CYFRA 21−1 in cervical cancer patients treated with radiation therapy.// J Cancer Res Clin Oncol.-2000.-Vol.126.-N6.-p.332−6.
- Tabata Т., Takeshima N., Tanaka N. et al. Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma.// Tumor Biol.-2000.-Vol.21.-N6.-p.375−80.
- Tada A., Kawai H., Matsumoto H. et al// Tumor markers of patients with lung cancer and patients with tuberculous pleurisy.// Nihon Kokyuki Gakkai Zassi.-2002.-Vol.40.-N 2.-p. 106−112.
- Tageuchi S., Nonaka M., Kadokura M. Prognostic significance of serum SCC antigen in surgically treated lung cancer.// Ann Thorac Cardiovasc Surg.-2003 .-vol.9.-N 2.-P.98−104.
- Takeda M., Sakuragi N., Okamoto K. et al. Preoperative serum SCC, CA 125 and CA 19−9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. // Acta Obstet Gynecol Scand.-2002.- vol. 81.-N5.-p.451−7.
- Takeda A., Higuchi D., Takahashi T. et al. Overexpression of serpin SCC antigens in psoriatic skin. // J invest Dermatol. -2002.-vol.l 18.-N l.-p.l47−154.
- Takeshi M., Shigeki Y., Takashi S. et al. Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix. // Tumor Biol.-1998-vol.19.- p. 494−504.
- Takeshima N., Suminami Y., Takeda O. et al. Expression of mRNA of SCC antigen in squamous cells//Tumor Biol.-1992.-Vol. 13.-p. 338−342.
- Takeshima N., Suminami Y., Takeda O. et al. Origin of CA 125 and SCC antigen in human amniotic fluid. // Asia-Oceania-J-Obstet-Gynaecol.-1993.-vol.19.-N 2.-p. 199−204.
- Tarle M. Serial measurements of TPS, PSA, PAP and CEA serotest values in treated patients with primary and metastatic ptostata cancer.// Anticancer Res 1998.-vol.13.-N 3.-p.769−77.
- Tatsura M., Nishi Т., Yamada T. et al. A case of bronchogenic cyst in the posterior mediastinum with high level of serum SCC antigen. // Kyobu-Geka.-1993.-vol.46.-N7.-p.623−625.
- Tempfer C., Hefler L., Heuster G. et al. TPS in the follow-up of ovarian and cervical cancer patients. // Int J Cancer.-1998.-vol.79.-p.241−4.
- Tendler A., Kaufman H., Kadish A. Increaserd CEA expression in cervical intraepithelial neoplasia grade 3 and in cervical squamous cell carcinomas/Hum Pathol.-2000.-Vol.31.-Nl 1. -p. 1357−62.
- Theyer G., Holub S., Durer A. et al. Measurements of TPS and PSA in prostata cancer patients under intermittent androgen suppression therapy. //Br J Cancer.-1997.-vol.75.-N 10.-p.l515−8.
- Trevisani J., Putinati S., Saritor S. et al. Cytokeratin tumor markers levels in bronchial washing in the diagnosis of lung cancer.// Chest.-1998.-vol.109.-N 1.-p. 104−8.
- Tseng C., Chou H., Huang K. et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. // Gynecol-Oncol.-1996.-vol.63.-N 3.-p.364−370.
- Tu D., Wang S., Chang T. et al. The value of serum TPS in the diagnosis of the hepatocellular carcinoma.// Cancer.-1999.-vol.85.-N 5.-p.l039−43.
- Ueda S., Tsubura A., Sasaki M. et al. Immunohistochemical studies on CEA in adenocarcinomas of the uterus.// Acta Pathol Jpn.-1984.-Vol.33.-N1.-p.59−69.
- Vibert H., Houston A., Wilkins G. et al. CA 49 and TPS patterns in the diagnosis and staging of patients with breast carcinoma.// Int J Biol Markers.-1997.-vol.l l.-N 4.-p. 198−202.
- Weiderpass E. // Intern.conference^hormonal carcinogenesis.-2000.-p.22−23
- Wishnow K., Johnson D., Fritsche H. SCC antigen in genitourinary tumors. // Int-J-Biol-Markers.-1989.-vol.4.-N 4.-p.226−228.
- Wolff J., Borechers H., Brehmer B. et al. Cytokeratin markers in patients with prostatic diseases.// Anticancer res.-1999.-vol.19.-N 4.-p.2649−52.
- Wolff G., Rohde D., Borehers H. et al. TPS antigen serum concentrations in patients with newly diagnosed prostatic diseases.// Anticancer Res.-2000.-vol.20.-N 6.-p.5003−5.
- Yamawaki T., TakeshimaN., Shimixu Y. et al. Serum levels of SCC antigen and CEA as tumor markers of vulvar cancer. //J-Obstet-Gynaecol-Res.-1996.-vol.22.-N 4.-p.341−346.
- Yao W., Chang Т., Wang S. et al. Clinicopathologic correlation of serum TPS in hepatocellular carcinoma.// Oncology.-2002.-vol.61.-N l.-p.64−70.
- Yao W., Wang S., Chang T. et al. Serum TPS as a noninvasive prognostic indicator for early reccurence of hepatocellular carcinoma after curative resection.// Cancer.-2002.-vol.95.-N l.-p.l 12−8.
- Yazigi R., Castillo R., Aliste G. Et al. CYFRA 21−1 marker in carcinoma of the cervix.// Int J Gynecol Cancer.-2000.-Vol.10.-N 3.-p.203−206.
- Ychou M., Khemissa-Akhouz F., Kramar A. et al. A comparison of serum CYFRA 21−1 and SCC antigen in the diagnosis of squamous cell esophageal carcinoma. //Bull Cancer.-2001.- vol.88.-N 10.-p.l023−7.
- Yeh L., Hung Y., Kao A. et al. TPS and CA 125 in the early prediction of recurrent ovarian cancer.// Anticancer Res.-2002.-vol.22.-N6.-p.3669−71.
- Yuan C., Wang P., Tsai L. et al. Both TPA and SCC-Ag levels a prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. // Eur J Gynaecol Oncol.- 2002.-vol.23.-N l.-p.l7−20.
- Zakrzewska J., Borawska R. The value of serum TPS concentrations in therapeutic monitoring of patients with epithelial malignant ovarian neoplasms.//Gynecol PoL-2000.-vol.7 l.-N 12.-p.l523−31.
- Zacrzewska J. The value of markers antigens TPS, SCC and CEA in diagnosis, evaluation of hystologic type and clinical disease progression in patients with cervical carcinoma.// Pol Merkuriusz Lek.-2002.-vol.10.-p.21−23.
- Zakrzewska J. TPS and SCC antigens in diagnosis and monitoring treatment of patients with cervical cancer.// Gynecol Pol.-2002.-vol.72.-p.854−61.
- Zheng H., He В., Luo R. et al. Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer.// Di Y Jun.-2003.-vol.23.-N 2.-p.l65−6.
- Zhu L., Li B. Histopathology and immunohistochemical expression of precursor lesions of cervical adenocarcinoma.// Zhonghua Bing Li Xue Za Zhi.-2001.-Vol.30.-N4.-p.249−52.
- Zygmunt A., Madry R., Markowska J. et al. Estimation of the usefulness of neoplastic markers TPS and С A 125 in diagnosis and monitoring of ovarian cancer.// Eur J Gynaecol C>ncol.-1999.-vol.20.-N 4.-p.298−301.